Literature DB >> 16777482

PPARs and other nuclear receptors in inflammation.

Giovanni Rizzo1, Stefano Fiorucci.   

Abstract

Inflammation is a central component of several chronic human diseases, including atherosclerosis and type 2 diabetes. Several nuclear receptors repress inflammatory responses, but their molecular mechanisms remain poorly understood. The nuclear receptor superfamily is composed of transcription factors that have emerged as key regulators of inflammation and lipid homeostasis. These include the glucocorticoid receptor, which inhibits inflammatory programs of gene expression in response to natural corticosteroids and synthetic anti-inflammatory ligands such as dexamethasone. In addition, peroxisome proliferator-activated receptors and liverXreceptors, in response to endogenous eicosanoids and oxysterols, respectively, modulate transcriptional pathways involved in inflammatory responses and lipid homeostasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777482     DOI: 10.1016/j.coph.2006.03.012

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  39 in total

Review 1.  Adopting new orphans into the family of metabolic regulators.

Authors:  Sarah Hummasti; Peter Tontonoz
Journal:  Mol Endocrinol       Date:  2008-02-07

Review 2.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

3.  Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival.

Authors:  Costantinos Giaginis; Ekaterini Politi; Paraskevi Alexandrou; John Sfiniadakis; Gregory Kouraklis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

4.  Liver X receptor-activating ligands modulate renal and intestinal sodium-phosphate transporters.

Authors:  Yupanqui A Caldas; Hector Giral; Michael A Cortázar; Eileen Sutherland; Kayo Okamura; Judith Blaine; Victor Sorribas; Hermann Koepsell; Moshe Levi
Journal:  Kidney Int       Date:  2011-06-15       Impact factor: 10.612

5.  PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.

Authors:  Wen Huang; Sung Yong Eum; Ibolya E András; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

Review 6.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

7.  High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.

Authors:  Frank H Niesen; Lena Schultz; Ajit Jadhav; Chitra Bhatia; Kunde Guo; David J Maloney; Ewa S Pilka; Minghua Wang; Udo Oppermann; Tom D Heightman; Anton Simeonov
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

8.  Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.

Authors:  Heather E Ferguson; Ajit Kulkarni; Geniece M Lehmann; Tatiana M Garcia-Bates; Thomas H Thatcher; Krystel R Huxlin; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-13       Impact factor: 6.914

9.  Identification of an inter-transcription factor regulatory network in human hepatoma cells by Matrix RNAi.

Authors:  Yasuhiro Tomaru; Misato Nakanishi; Hisashi Miura; Yasumasa Kimura; Hiroki Ohkawa; Yusuke Ohta; Yoshihide Hayashizaki; Masanori Suzuki
Journal:  Nucleic Acids Res       Date:  2009-01-07       Impact factor: 16.971

10.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.